Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott E Strome

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Expert Opinion on Biological Therapy|October 6, 2004
B7-H1-targeted immunotherapy for head and neck cancerXiaoyu Zhang, Scott E Strome
Current Treatment Options in Oncology|December 31, 2003
Costimulation-based immunotherapy for head and neck cancerScott E Strome, Lieping Chen
Oral Oncology|May 14, 2014
The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neckDan P Zandberg, Scott E Strome
Current Treatment Options in Oncology|June 12, 2002
Advanced larynx cancerScott E Strome, Eric C Weinman
Laryngoscope Investigative Otolaryngology|March 5, 2019
The evolving role of immuno-oncology for the treatment of head and neck cancerArianna L Strome, Xiaoyu Zhang, Scott E Strome
The Oncologist|October 5, 2007
A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effectsScott E Strome, Edward A Sausville, Dean Mann
Current Molecular Medicine|August 20, 2009
Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcomeCaroline J Voskens, Scott E Strome, Duane A Sewell
Oral Oncology|August 10, 2016
The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatmentSara I Pai, Dan P Zandberg, Scott E Strome
Vaccine|September 29, 2011
Bone marrow vaccination: a novel approach to enhance antigen specific antitumor immunityStephanie Fresnay, Xiaoyu Zhang, Scott E Strome, et al.
Trends in Biotechnology|December 10, 2014
Fc fusion as a platform technology: potential for modulating immunogenicityDitza Levin, Basil Golding, Scott E Strome, et al.
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Expert Opinion on Biological Therapy|October 6, 2004
B7-H1-targeted immunotherapy for head and neck cancerXiaoyu Zhang, Scott E Strome
Current Treatment Options in Oncology|December 31, 2003
Costimulation-based immunotherapy for head and neck cancerScott E Strome, Lieping Chen
Oral Oncology|May 14, 2014
The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neckDan P Zandberg, Scott E Strome
Current Treatment Options in Oncology|June 12, 2002
Advanced larynx cancerScott E Strome, Eric C Weinman
Laryngoscope Investigative Otolaryngology|March 5, 2019
The evolving role of immuno-oncology for the treatment of head and neck cancerArianna L Strome, Xiaoyu Zhang, Scott E Strome
The Oncologist|October 5, 2007
A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effectsScott E Strome, Edward A Sausville, Dean Mann
Current Molecular Medicine|August 20, 2009
Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcomeCaroline J Voskens, Scott E Strome, Duane A Sewell
Oral Oncology|August 10, 2016
The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatmentSara I Pai, Dan P Zandberg, Scott E Strome
Vaccine|September 29, 2011
Bone marrow vaccination: a novel approach to enhance antigen specific antitumor immunityStephanie Fresnay, Xiaoyu Zhang, Scott E Strome, et al.
Trends in Biotechnology|December 10, 2014
Fc fusion as a platform technology: potential for modulating immunogenicityDitza Levin, Basil Golding, Scott E Strome, et al.
Pageof 9